Cargando…

Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy?

BACKGROUND: It is a critical unmet need to predict chemosensitivity in muscle-invasive bladder cancer patients who receive neoadjuvant chemotherapy (NAC). Quantification of tumor heterogeneity has been shown to be useful in the assessment of therapeutic response. Apparent diffusion coefficient (ADC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Huyen T., Mortazavi, Amir, Pohar, Kamal S., Zynger, Debra L., Wei, Lai, Shah, Zarine K., Jia, Guang, Knopp, Michael V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2017
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676757/ https://www.ncbi.nlm.nih.gov/pubmed/29152548 http://dx.doi.org/10.3233/BLC-170110

Ejemplares similares

Periodically rotated overlapping parallel lines with enhanced reconstruction acquisition to improve motion-induced artifacts in bladder cancer imaging: Initial findings
por: Nguyen, Huyen Thanh, et al.
Publicado: (2019)

Diffusion-weighted MRI to determine response and long-term clinical outcomes in muscle-invasive bladder cancer following neoadjuvant chemotherapy
por: Hafeez, Shaista, et al.
Publicado: (2022)

Oncological outcomes of visibly complete transurethral resection prior to neoadjuvant chemotherapy for bladder cancer
por: Baird, Bryce, et al.
Publicado: (2023)

Diffusion-weighted MRI and histogram analysis: assessment of response to neoadjuvant chemotherapy in nephroblastoma
por: Hötker, Andreas M., et al.
Publicado: (2021)

Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
por: Sherif, Amir, et al.
Publicado: (2018)

Neoadjuvant Chemotherapy in Invasive Bladder Cancer
por: Oliver, R.T.D.
Publicado: (1991)

Implanted markers prior to neoadjuvant chemotherapy: preliminary report
por: Allan for the Dartford Breast Care Team, DM
Publicado: (2000)

Assessment of diffusion-weighted MRI in predicting response to neoadjuvant chemotherapy in breast cancer patients
por: Hottat, Nathalie A., et al.
Publicado: (2023)

Breast DCE-MRI Kinetic Heterogeneity Tumor Markers: Preliminary Associations With Neoadjuvant Chemotherapy Response()
por: Ashraf, Ahmed, et al.
Publicado: (2015)

Pretreatment Diffusion-Weighted MRI Can Predict the Response to Neoadjuvant Chemotherapy in Patients with Nasopharyngeal Carcinoma
por: Zhang, Guo-Yi, et al.
Publicado: (2015)

von Brunn's Nests and Follicular Cystitis Following Intradetrusor OnabotulinumtoxinA Injections for Overactive Bladder
por: Nekkanti, Silpa, et al.
Publicado: (2017)

Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy
por: Sui, Wilson, et al.
Publicado: (2017)

Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer
por: Deen, Surrin S., et al.
Publicado: (2019)

Efficacy Evaluation of Neoadjuvant Chemotherapy in Breast Cancer by MRI
por: Liu, Yongguang, et al.
Publicado: (2022)

Heterogeneity of Circulating Tumor Cells in Neoadjuvant Chemotherapy of Breast Cancer
por: Kaigorodova, Evgeniya V., et al.
Publicado: (2018)

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
por: Jayaratna, Isuru S., et al.
Publicado: (2015)

Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report
por: Prelaj, Arsela, et al.
Publicado: (2016)

Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer
por: Carvalho, Filipe LF., et al.
Publicado: (2020)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Development of a MRI-Based Radiomics Nomogram for Prediction of Response of Patients With Muscle-Invasive Bladder Cancer to Neoadjuvant Chemotherapy
por: Zhang, Xinxin, et al.
Publicado: (2022)

Prediction of Poor Responders to Neoadjuvant Chemotherapy in Patients with Osteosarcoma: Additive Value of Diffusion-Weighted MRI including Volumetric Analysis to Standard MRI at 3T
por: Lee, Seul Ki, et al.
Publicado: (2020)

Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Guancial, Elizabeth A., et al.
Publicado: (2016)

Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration
por: Jahani, Nariman, et al.
Publicado: (2019)

An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer
por: Xylinas, Evanguelos, et al.
Publicado: (2016)

Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
por: McFerrin, Coleman, et al.
Publicado: (2020)

Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Miyagi, Hiroko, et al.
Publicado: (2022)

Early Prediction and Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy Using Quantitative DCE-MRI()
por: Tudorica, Alina, et al.
Publicado: (2016)

Diffusion-weighted MRI for predicting pathologic response to neoadjuvant chemotherapy in breast cancer: evaluation with mono-, bi-, and stretched-exponential models
por: Suo, Shiteng, et al.
Publicado: (2021)

Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer
por: Liang, Xinhong, et al.
Publicado: (2022)

Quantitative Dynamic-Enhanced MRI and Intravoxel Incoherent Motion Diffusion−Weighted Imaging for Prediction of the Pathological Response to Neoadjuvant Chemotherapy and the Prognosis in Locally Advanced Gastric Cancer
por: Zhu, Yongjian, et al.
Publicado: (2022)

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
por: Li, Wen, et al.
Publicado: (2022)

Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting
por: Virostko, John, et al.
Publicado: (2021)

Quantitative DCE-MRI prediction of breast cancer recurrence following neoadjuvant chemotherapy: a preliminary study
por: Thawani, Rajat, et al.
Publicado: (2022)

Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?
por: Glynne-Jones, R, et al.
Publicado: (2006)

The long perspective in emergence of neoadjuvant chemotherapy for bladder cancer in Ontario, Canada—space for improvement with regular and organized multidisciplinary team meetings
por: Sherif, Amir
Publicado: (2018)

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion
por: Eldefrawy, Ahmed, et al.
Publicado: (2012)

Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions
por: Cowan, N. G., et al.
Publicado: (2014)

Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience
por: Yu, Bin, et al.
Publicado: (2015)

Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer
por: Marcq, Gautier, et al.
Publicado: (2019)

Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy
por: Font, Albert, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iir7kfm76mk2tfio6a5m5er3jo